Insight

Bettina Ryll: Valerie Diane Valeriano at MPNE Hubs 2024 on how the microbiome modulates response to immune therapies in Melanoma

Valerie Diane Valeriano and Bettina Ryll

Dec 9, 2024, 14:45

Bettina Ryll: Valerie Diane Valeriano at MPNE Hubs 2024 on how the microbiome modulates response to immune therapies in Melanoma

Bettina Ryll, Founder of MPN Europe, shared on LinkedIn:

“Listening to Valerie Diane Valeriano at MPNEhubs 2024 on how the microbiome modulates response to immune therapies in Melanoma and her work in the OncoBiome project.

A lot of considerations to turn an observation into something that could become a treatment a scale- and why designer microbiome consortia might be a good concept.

If you want to meet someone passionate about microbiota- you have to meet Valerie Diane Valeriano.”

Bettina Ryll

Article 1: Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Bettina Ryll

Article 2: Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

Bettina Ryll

More posts featuring Bettina Ryll.

anti-PD-1 therapy Bettina Ryll cancer Fecal microbiota Genomic heterogeneity Melanoma melanoma patients metastatic melanoma microbiome microbiota MPNEhubs OncoDaily Oncology patients ploidy identify Valerie Diane Valeriano

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to Oncodaily on Pediatric Oncology Funding

Does Processed Meat Cause Cancer? Myths and Facts

Global Health Dialogues with Princess Dina Mired | Episode 1: Dr. Firas Al-Hawari

NEW PAPER ALERT: ESOPEC trial on Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer